Skip to content

Study · Non-randomized trial · n = 44 · 2012

3 results

Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients.

Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT

The oncologist26 Jan 2012Cited by 23 (Europe PMC)

PMID22282904 (opens in a new tab)PMCIDPMC3286172 (opens in a new tab)DOI10.1634/theoncologist.2011-0205 (opens in a new tab)PepBankPUB-22282904
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    Among women receiving leuprolide before HSCT, seven of 44 patients (16%) regained ovarian function.

    In plain wordsAmong women receiving leuprolide before stem cell transplantation, seven of 44 (16%) regained ovarian function.

    Peptide
    Leuprolide
    Outcome
    Not applicableOvarian function recovery
    Study

    n = 44

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Two 22.5-mg doses · intramuscularAs given in this study (human).

    Measurements

    Patients who regained ovarian function
    7 patients
    of 44 evaluable after leuprolide before HSCT
    Proportion regaining ovarian function
    16%
    44 evaluable patients

    Source sentences

    Summary
    Only seven of 44 patients (16%) regained ovarian function.
    2 context sentences
    Summary · context
    Two 22.5-mg leuprolide doses were delivered in 3-month depot i.m. injections, the first within 2 months before HSCT.
    Summary · context
    Sixty eligible patients were enrolled, 59 underwent HSCT, and 44 were evaluable (median age, 25 years; median follow-up, 355 days).
  2. 02HumanNon-randomized trialEfficacy outcome

    Among women receiving leuprolide and myeloablative HSCT regimens, six of 33 (18%) regained ovarian function.

    In plain wordsAmong women receiving leuprolide and myeloablative transplantation regimens, six of 33 (18%) regained ovarian function.

    Peptide
    Leuprolide
    Outcome
    Not applicableOvarian recovery after myeloablative conditioning
    Study

    n = 33

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Two 22.5-mg doses · intramuscularAs given in this study (human).

    Measurements

    Patients who regained ovarian function
    6 patients
    of 33 with myeloablative regimens
    Proportion regaining ovarian function
    18%
    33 with myeloablative regimens

    Source sentences

    Summary
    Of the 33 who received myeloablative regimens, six (18%) regained ovarian function.
    2 context sentences
    Summary · context
    Two 22.5-mg leuprolide doses were delivered in 3-month depot i.m. injections, the first within 2 months before HSCT.
    Summary · context
    Sixty eligible patients were enrolled, 59 underwent HSCT, and 44 were evaluable (median age, 25 years; median follow-up, 355 days).
  3. 03HumanNon-randomized trialEfficacy outcome

    Among women receiving leuprolide and nonmyeloablative HSCT regimens, one of 11 (9%) regained ovarian function.

    In plain wordsAmong women receiving leuprolide and nonmyeloablative transplantation regimens, one of 11 (9%) regained ovarian function.

    Peptide
    Leuprolide
    Outcome
    Not applicableOvarian recovery after nonmyeloablative conditioning
    Study

    n = 11

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Two 22.5-mg doses · intramuscularAs given in this study (human).

    Measurements

    Patients who regained ovarian function
    1 patients
    of 11 with nonmyeloablative regimens
    Proportion regaining ovarian function
    9%
    11 with nonmyeloablative regimens

    Source sentences

    Summary
    However, among the 11 who received nonmyeloablative regimens, only one (9%) regained ovarian function (p = .66).
    2 context sentences
    Summary · context
    Two 22.5-mg leuprolide doses were delivered in 3-month depot i.m. injections, the first within 2 months before HSCT.
    Summary · context
    Sixty eligible patients were enrolled, 59 underwent HSCT, and 44 were evaluable (median age, 25 years; median follow-up, 355 days).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00429494

GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients

M.D. Anderson Cancer Centern = 60Nov 2002 to Jun 2011

Amenorrhea · Premature Ovarian Failure · Ovarian Function Insufficiency

Trial pageClinicalTrials.govUpdated 9 Jul 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.